Filtered By:
Drug: Fortamet

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 9822 results found since Jan 2013.

Hypoglycemia, Treatment Discontinuation, and Costs in Patients with Type 2 Diabetes Mellitus on Oral Antidiabetic Drugs
Conclusion: Different OAD classes were associated with different levels of risk for hypoglycemic events. Hypoglycemia was associated with a higher risk of antidiabetic treatment discontinuation and significantly increased health care costs. Keywords: hypoglycemia; type 2 diabetes mellitus; oral antidiabetic drug; treatment discontinuation; health care cost read more
Source: Postgraduate Medicine Online - February 3, 2012 Category: Internal Medicine Authors: admin Source Type: research

Identification and replication of prediction models for ovulation, pregnancy and live birth in infertile women with polycystic ovary syndrome
STUDY QUESTION Can we build and validate predictive models for ovulation and pregnancy outcomes in infertile women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER We were able to develop and validate a predictive model for pregnancy outcomes in women with PCOS using simple clinical and biochemical criteria particularly duration of attempting conception, which was the most consistent predictor among all considered factors for pregnancy outcomes. WHAT IS KNOWN ALREADY Predictive models for ovulation and pregnancy outcomes in infertile women with polycystic ovary syndrome have been reported, but such models require va...
Source: Human Reproduction - August 19, 2015 Category: Reproduction Medicine Authors: Kuang, H., Jin, S., Hansen, K. R., Diamond, M. P., Coutifaris, C., Casson, P., Christman, G., Alvero, R., Huang, H., Bates, G. W., Usadi, R., Lucidi, S., Baker, V., Santoro, N., Eisenberg, E., Legro, R. S., Zhang, H., for the Reproductive Medicine Network Tags: Reproductive epidemiology Source Type: research

What Trump’s Plan to Negotiate With Pharma Should Tell Us
By JK WALL Donald Trump’s proposal to allow the federal Medicare program to negotiate prices with drug companies should be a wake-up call for the pharmaceutical industry. Trump is leading in the polls for the Republican nomination and is even drawing the support of Tea Party conservatives who, just a year or two ago, never would have supported a candidate endorsing such strong government intervention into a private-sector industry. Characteristically, Trump didn’t give a lot of detail about his plans. He claimed $300 billion in savings per year (about 10 times more than is realistic). But that doesn’t matter. If the...
Source: The Health Care Blog - January 31, 2016 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Source Type: blogs

Comparison of use of diabetic medication and clinical guidelines in four Nordic countries.
Conclusions All guidelines stress regular and comprehensive diabetes care. Danish and Finnish guidelines strongly underline the importance of individualized glycemic targets. All guidelines recommend metformin as the initial oral antihyperglycemic drug. In relation to recommended second line drug therapy and initial insulin type for patients with T2D, the guidelines vary largely between the four countries. Key messages All Nordic guidelines for treating type 2 diabetes stress the importance of comprehensive care. The Danish and Finnish guidelines underline the importance of individualized glycemic targets. The first line a...
Source: Annals of Medicine - February 19, 2016 Category: Internal Medicine Tags: Ann Med Source Type: research

What Trump’s Plan to Negotiate With Pharma Should Tell Us
By JK WALL Donald Trump’s proposal to allow the federal Medicare program to negotiate prices with drug companies should be a wake-up call for the pharmaceutical industry. Trump is leading in the polls for the Republican nomination and is even drawing the support of Tea Party conservatives who, just a year or two ago, never would have supported a candidate endorsing such strong government intervention into a private-sector industry. Characteristically, Trump didn’t give a lot of detail about his plans. He claimed $300 billion in savings per year (about 10 times more than is realistic). But that doesn’t matter. If the...
Source: The Health Care Blog - March 3, 2016 Category: Consumer Health News Authors: John Irvine Tags: Economics Uncategorized Source Type: blogs

Drugs for the treatment of pediatric type 2 diabetes mellitus and related co-morbidities.
This article has reviewed clinical practice guidelines, particularly the American Diabetes Association and the Pediatric Endocrine Society consensus, jointly with clinical trial data available in databases with respect to the use of available pharmacological options to treat T2DM and its complications in youth. Expert opinion The use of other pharmacological treatments of T2DM in addition to metformin and insulin entails several problems. Since rare studies have been conducted on the medications available to manage T2DM in children, treating them may be more difficult than that of adults. It needs longer and larger size cl...
Source: Expert Opinion on Pharmacotherapy - November 9, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Incentive-Based Systems to Improve Patient Compliance: Interview with Matt Loper, CEO of Wellth
Wellth, a digital health company based in New York, has developed a system that provides patients with daily financial incentives to improve their compliance with drug regimens. Low patient compliance results in significant issues in terms of patient...
Source: Medgadget - August 14, 2017 Category: Medical Devices Authors: Conn Hastings Tags: Exclusive Geriatrics Medicine Public Health Source Type: blogs

The present and future treatment of pediatric type 2 diabetes.
Authors: Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W Abstract INTRODUCTION: Treatment of type 2 diabetes (T2D) in children and adolescents is particularly challenging. Metformin monotherapy is the standard initial treatment for youth with T2D, once metabolic control is restored with insulin in patients who present with ketosis and/or marked hyperglycemia. Insulin, the only other drug approved for use in youth with T2D, is also used as add-on therapy when patients fail metformin mono-therapy. Areas covered: In this paper, we will summarize the current use of both metformin and insulin in the treatmen...
Source: Expert Review of Endocrinology and Metabolism - August 2, 2018 Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research

Network Medicine: A Clinical Approach for Precision Medicine and Personalized Therapy in Coronary Heart Disease.
Authors: Infante T, Viscovo LD, Rimini ML, Padula S, Caso P, Napoli C Abstract Early identification of coronary atherosclerotic pathogenic mechanisms is useful for predicting the risk of coronary heart disease (CHD) and future cardiac events. Epigenome changes may clarify a significant fraction of this "missing hereditability", thus offering novel potential biomarkers for prevention and care of CHD. The rapidly growing disciplines of systems biology and network science are now poised to meet the fields of precision medicine and personalized therapy. Network medicine integrates standard clinical recording and non-in...
Source: Journal of Atherosclerosis and Thrombosis - November 16, 2019 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

The Public Cannot Distinguish Between Scientific versus Unscientific, Likely Good versus Likely Bad Approaches to Longevity
One of the challenges inherent in patient advocacy for greater human longevity, for more research into aging and rejuvenation, is that journalists and the public at large either cannot or will not put in the effort needed to distinguish between: (a) scientific, plausible, and likely useful projects, those with a good expectation of addressing aging to a meaningful degree; (b) scientific, plausible, and likely unhelpful projects, those that will do little to move the needle on life expectancy, and (c) products and programs that consist of marketing, lies, and little else. This last category is depressingly large, and the fi...
Source: Fight Aging! - August 20, 2020 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs

Metformin-induced Lactic Acidosis Reported in the Youngest Pediatric Patient with Impaired Renal Function.
Authors: Al-Abdwani R Abstract Metformin is a widely used biguanide for the treatment of type 2 diabetes mellitus. Metformin-induced lactic acidosis (MALA) is a rare but potentially fatal entity in the pediatric age group, seen mainly in suicide attempts in adolescents. MALA has not yet been reported in younger patients or pediatric patients taking regular therapeutic doses. Here, we report a three-year-old female receiving therapeutic metformin who developed MALA. MALA should be suspected in patients with unexplained lactic acidosis and on regular metformin, especially in the setting of renal impairment or hypoxic...
Source: Oman Medical Journal - September 22, 2020 Category: Middle East Health Tags: Oman Med J Source Type: research

Does Metformin Treatment in Pediatric Population Cause Vitamin B12 Deficiency?
Conclusion Although no significant changes in the serum vitamin B12, homocysteine, MMA or holo-TC-II levels with metformin therapy were detected, long-term prospective studies with high-dose metformin treatment in pediatric population are needed to confirm our results. [...] Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Klinische Padiatrie - February 3, 2022 Category: Pediatrics Authors: Ta ş, Özen Kontbay, Tugba Dogan, Ozlem Kose, Engin Berberoglu, Merih Siklar, Zeynep Tumer, Leyla Eminoglu, Fatma Tuba Tags: Original Article Source Type: research

Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register
This study shows a poor adherence to current guidelines on diabetes management in hospitalized elderly people with a high prevalence of inappropriate use of sul fonylureas according to the Beers criteria.
Source: Internal and Emergency Medicine - March 25, 2023 Category: Emergency Medicine Source Type: research

Alfie Health ’ s New AI-Powered ObesityRx Platform Helps Determine Sustainable Weight Loss Approach for Patients with Obesity, Using Precision Medicine and Telehealth Support
With $2.1 Million in Funding, Alfie Health Reports a Cohort of 300 Patients Lost an Average of 10-15% of Body Weight over Nine Months of Following its Holistic Approach The AI Platform Analyzes Patient Data, Recommends Medication (or Combination Meds) Precisely Prescribed, as well as Behavioral Changes, and Provides Ongoing Telehealth Support With 42 percent of Americans now struggling with obesity, doctors and their patients are looking for a sustainable approach to weight loss. Currently, prescription medications known as the GLP-1 class of anti-obesity medications (such as Ozempic®, Wegovy®, Mounjaro, etc.) are becomi...
Source: EMR and HIPAA - July 21, 2023 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT Alexander Singh Alfie Health Cleveland Clinic Cleveland Clinic's Bariatric and Metabolic Institute Dr. W. Scott Butsch GLP-1 Goodwater Capital Health IT Funding Health IT Fundings Health IT Investment Source Type: blogs